Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
Clinical Trials
The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of an active drug in subjects with progressive supranuclear palsy (PSP).
The purpose of this study is to assess the long-term safety and efficacy of an active drug in subjects with progressive supranuclear palsy (PSP). In a subset of participants at participating sites, participants will be assigned digital sensor BioStamp to
Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with an active drug.
The main objective of this study is to evaluate the efficacy and safety of an active drug compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
This was a Canadian post-marketing observational study (PMOS) utilizing a prospective cohort design that compared the real - life effectiveness of an active drug to topical and traditional systemic agents in the management of psoriasis and its impact on
Plaque Psoriasis is a chronic inflammatory disease in which skin cells build up and develop scaly red and white patches on the skin. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. Palmoplantar (non-pustular)
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate
Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study will assess how safe and effective cedirogant (ABBV-157) is compared to placebo in adult participants with
The purpose of this study is to compare the safety and efficacy of an active drug versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).
An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in subjects with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 is designed to compare the achievement of minimal disease activity (MDA) between
This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of an active drug Dose A once daily (QD) and Dose B QD versus placebo and versus an active drug every other week (eow) in
This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of an active drug Dose A once daily (QD) and Dose B QD versus placebo in participants with moderately to severely active
The current study will assess the real - life effectiveness of an active drug in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by the body's immune system mistakenly attacking healthy joint
The purpose of this study is to evaluate the safety and efficacy of an active drug in patients with moderately to severely active psoriatic arthritis (PsA).
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain (IBP) that might be difficult to distinguish from other causes of
This is a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in subjects with relapsed or refractory multiple myeloma who are considered sensitive or
The purpose of this study is to describe the impact of treatment with an active drug on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with an active drug versus placebo and versus an active comparator, an active drug, in adults with with moderately to severely active rheumatoid
The objectives of Period 1 were the following:
1. To compare the safety and efficacy of an active drug 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate